<DOC>
	<DOC>NCT01940965</DOC>
	<brief_summary>Primary Objective: The primary objective of this study is to assess the overall safety of lixisenatide once daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in patients with type 2 diabetes in Japan. Secondary Objective: To assess the effects of lixisenatide in combination with background oral antidiabetic drug (OAD) on: - HbA1c; - Fasting plasma glucose; - Body weight.</brief_summary>
	<brief_title>Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>54 weeks +/-11 days</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criteria : Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label a biguanide (metformin hydrochloride); a thiazolidinedione (TZD) (pioglitazone hydrochloride); an alphaglucosidase inhibitor (alphaGI) (acarbose, voglibose or miglitol); or a glinide (nateglinide, repaglinide or mitiglinide); Signed written informed consent Exclusion criteria: At screening HbA1c &lt;7% or &gt;9.5%; At screening: fasting plasma glucose &gt;250 mg/dL (&gt;13.9 mmol/L); Use of any glucoselowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening; Type 1 diabetes mellitus; Women of childbearing potential with no effective contraceptive method; Pregnancy or lactation; Laboratory findings at the time of screening: Amylase and/or lipase &gt;3 times the upper limit of the normal laboratory range (ULN); ALT &gt;3 ULN; Any contraindication to the patient's background oral antidiabetic treatment; History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease; Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes); Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>